Table of Contents
1 Introduction
1.1 Objectives and Scope
1.2 Research Methodology
1.3 Market Estimation Methodology
1.4 Primary Research Methodology
1.5 Primary Respondent Profile
2 Key Insights
3 Therapeutic Plasma Exchnage Market, By Indication
3.1 Guillain-Barré Syndrome (GBS)
3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
3.3 Myasthenia Gravis (MG)
3.4 Multiple Sclerosis (MS)
3.5 Neuromyelitis Optica (NMO)
3.6 Thrombotic Thrombocytopenic Purpura (TTP)
3.7 Cryoglobulinemia
3.8 Multiple Myeloma (MM)
3.9 Waldenstrom Macroglobulinemia (WM)
3.10 Hemolytic Uremic Syndrome (HUS)
3.11 Anti-GBM Disease (Goodpasture’s Syndrome)
3.12 Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis)
3.13 Post-Renal Transplant Rejection
3.14 Familial Hypercholesterolemia (Homozygous)
3.15 Anca-Associated Vasculitis
4 Appendix
4.1 Epidemiology Data
4.2 Industry Speaks
4.3 Details of Primary Respondents
4.4 Available Customizations
4.4.1 Company Profiles
4.4.1.1 Fresenius Se & Co. KGAA
4.4.1.2 B. Braun Melsungen AG
4.4.1.3 Baxter International Inc
4.4.1.4 Asahi Kasei Medical Co., Ltd.
4.4.1.5 Terumo BCT, Inc.
4.4.1.6 Haemonetics Corporation
4.4.1.7 Kawasumi Laboratories, Inc.
4.4.1.8 Hemacare Corporation
4.5 Knowledge Store: Marketsandmarkets’ Subscription Portal
Table 1 Data Model
Table 2 U.S.: Therapeutic Plasma Exchange Market Size, By Indication, 2014–2021 (USD Million)
Table 3 U.S.: Therapeutic Plasma Exchange Market– Patient Population and Number of Procedures
Table 4 U.S. Disease Statistics: Acute Inflammatory Demyelinating Polyneuropathy
Table 5 Treatment Guidelines & Protocols : Guillain-Barré Syndrome (GBS)
Table 6 Epidemiology : Guillain-Barré Syndrome (GBS)
Table 7 U.S. Disease Statistics: Chronic Inflammatory Demyelinating Polyneuropathy
Table 8 Treatment Guidelines & Protocols : Chronic Inflammatory Demyelinating Polyneuropathy
Table 9 Epidemiology : Chronic Inflammatory Demyelinating Polyneuropathy
Table 10 U.S. Disease Statistics: Myasthenia Gravis (MG)
Table 11 Treatment Guidelines & Protocols : Myasthenia Gravis (MG)
Table 12 Epidemiology : Myasthenia Gravis (MG)
Table 13 U.S. Disease Statistics: Multiple Sclerosis (MS)
Table 14 Treatment Guidelines & Protocols : Multiple Sclerosis (MS)
Table 15 Epidemiology : Multiple Sclerosis (MS)
Table 16 U.S. Disease Statistics: Neuromyelitis Optica (NMO)
Table 17 Treatment Guidelines & Protocols : Neuromyelitis Optica (NMO)
Table 18 Epidemiology : Neuromyelitis Optica (NMO)
Table 19 U.S. Disease Statistics: Thrombotic Thrombocytopenic Purpura (TTP)
Table 20 Treatment Guidelines & Protocols : Thrombotic Thrombocytopenic Purpura (TTP)
Table 21 Epidemiology : Thrombotic Thrombocytopenic Purpura (TTP)
Table 22 U.S. Disease Statistics: Cryoglobulinemia
Table 23 Treatment Guidelines & Protocols : Cryoglobulinemia
Table 24 Epidemiology : Cryoglobulinemia
Table 25 U.S. Disease Statistics: Multiple Myeloma (MM)
Table 26 Treatment Guidelines & Protocols : Multiple Myeloma (MM)
Table 27 Epidemiology : Multiple Myeloma (MM)
Table 28 U.S. Disease Statistics: Waldenstrom Macroglobulinemia (WM)
Table 29 Treatment Guidelines & Protocols : Waldenstrom Macroglobulinemia (WM)
Table 30 Epidemiology : Waldenstrom Macroglobulinemia (WM)
Table 31 U.S. Disease Statistics: Hemolytic Uremic Syndrome (HUS)
Table 32 Treatment Guidelines & Protocols : Hemolytic Uremic Syndrome (HUS)
Table 33 Epidemiology : Hemolytic Uremic Syndrome (HUS)
Table 34 U.S. Disease Statistics: Anti-GBM Disease (Goodpasture’s Syndrome)
Table 35 Treatment Guidelines & Protocols : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 36 Epidemiology : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 37 U.S. Disease Statistics: Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis
Table 38 Treatment Guidelines & Protocols : Wegener’s Granulomatosis
Table 39 Epidemiology : Wegener’s Granulomatosis
Table 40 U.S. Disease Statistics: Post-Renal Transplant Rejection
Table 41 Treatment Guidelines & Protocols : Post-Renal Transplant Rejection
Table 42 Epidemiology : Post-Renal Transplant Rejection
Table 43 U.S. Disease Statistics: Familial Hypercholesterolemia (Homozygous)
Table 44 Treatment Guidelines & Protocols : Familial Hypercholesterolemia (Homozygous)
Table 45 Epidemiology : Familial Hypercholesterolemia (Homozygous)
Table 46 U.S. Disease Statistics: Anca-Associated Vasculitis
Table 47 Epidemiology Data
Table 48 Details of Primary Respondents (1/8)
Table 49 Details of Primary Respondents (2/8)
Table 50 Details of Primary Respondents (3/8)
Table 51 Details of Primary Respondents (4/8)
Table 52 Details of Primary Respondents (5/8)
Table 53 Details of Primary Respondents (6/8)
Table 54 Details of Primary Respondents (7/8)
Table 55 Details of Primary Respondents (8/8)
List of Figures (10 Figures)
Figure 1 Research Methodology
Figure 2 Market Estimation Methodology
Figure 3 Primary Research Methodology
Figure 4 Respondent Profile, By Organization
Figure 5 Respondent Profile, By Designation
Figure 6 Industry Speaks (1/3)
Figure 7 Industry Speaks (2/3)
Figure 8 Industry Speaks (3/3)
Figure 9 Marketsandmarkets Knowledge Store Snapshot
Figure 10 Marketsandmarkets Knowledge Store: Healthcare Industry Snapshot
【レポートのキーワード】
治療的血漿交換、血漿交換療法、アメリカ、疾患、医療